-
Biden’s Executive Order Boosts US Bio-Economy, Targets China’s Biotech Rise
•
US President Joe Biden signed an executive order on Monday, outlining steps to bolster the country’s bio-economy across industries ranging from agriculture and biofuels to medical supplies and bio-pharma manufacturing. The order, titled “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” aims to reduce US…
-
QuantuMDx and Sansure Biotech Partner to Commercialize Q-POC in China
•
UK-based QuantuMDx Group Ltd announced a global R&D, manufacturing, and commercial partnership with China’s Sansure Biotech Inc. The collaboration aims to accelerate the market penetration and commercialization of QuantuMDx’s Q-POC platform and related assays in China. Q-POC is a rapid, portable multiplex PCR device designed for real-world healthcare settings and…
-
InnoCare Pharma’s BCL2 Inhibitor ICP-248 Gains NMPA Approval for Clinical Study
•
China’s Beijing InnoCare Pharma (HKG: 9969) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its in-house developed BCL2 inhibitor, ICP-248. This Category 1 innovative drug becomes the company’s fifth drug to reach clinical trials in the blood cancer field…
-
BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase III RATIONALE 301 study evaluating tislelizumab in first-line unresectable hepatocellular carcinoma (HCC) at the 2022 European Society for Medical Oncology (ESMO) meeting. The study, which enrolled 674 patients in the US, Europe, and Asia, met…
-
Luye Pharma’s BA-CovMab Receives NMPA Approval for COVID-19 Clinical Trials
•
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s BA-CovMab, a broad-spectrum neutralizing antibody against COVID-19, has obtained clinical trial approval from the National Medical Products Administration (NMPA). Mechanism of ActionBA-CovMab is a recombinant fully human monoclonal neutralizing antibody obtained through sequential immunization and…
-
Jiangsu Healthcare to Cover All Psychological Treatments Under BMI
•
The Jiangsu Provincial Healthcare Security Administration is reportedly considering adding all psychological diagnosis and treatment items to the basic medical insurance (BMI) payment scope. The move aims to standardize payment categories, ratios, and standards on a provincial scale, with implementation expected by the end of October this year. Background and…
-
Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices
•
Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD 14.4 million) in a Series A financing round led by Proxima Ventures and Med-Fine Capital. Other investors included TigerYeah Capital, Maron Investment, and Cowin Capital. The proceeds will be used for research and development (R&D)…
-
Transcenta’s TST001 Shows Promise in Gastric Cancer Trial with 73.3% Response Rate
•
China-based biotech Transcenta Holdings Ltd (HKG: 6628) announced interim safety and efficacy data from a Phase I/II study of TST001 (osemitamab), a humanized ADCC-enhanced anti-Claudin18.2 monoclonal antibody (mAb), in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment for locally advanced or metastatic gastric or gastroesophageal junction (GC/GEJ) cancer.…
-
CSPC Pharmaceutical’s TG103 Gains NMPA Approval for NASH and Alzheimer’s Trials
•
China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct separate clinical trials for its Category 1 biologic product TG103 in non-alcoholic steatohepatitis (NASH) and Alzheimer’s disease (AD). This marks a significant step forward in the development…
-
Jingxin Pharmaceutical Receives NMPA Approval for JBPOS0101 and JX7002 Trials
•
Jingxin Pharmaceutical Co., Ltd (SHE: 002020) announced that it has received clinical trial approvals from the National Medical Products Administration (NMPA) for its in-licensed products JBPOS0101 and JX7002. JBPOS0101 is being assessed for focal epilepsy in adults, while JX7002 is under development for hypercholesterolemia and mixed hyperlipidemia. JBPOS0101: A First-in-Class…
-
China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021
•
According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug purchase” model has gained significant traction due to the COVID-19 pandemic and online prescription drug sales policies, with O2O becoming a mainstream retail pharmacy online business approach. By the end of 2021, approximately 200,000 pharmacies…
-
National High-Value Medical Consumables VBP Round Targets Orthopedic Spine Products
•
The national high-value medical consumables joint procurement office released a set of guiding opinions on the national high-value medical consumables volume-based procurement (VBP), publishing the filing invitation and procurement volume for orthopedic spine medical consumable products. The VBP round will include anterior cervical screw plates, posterior cervical screw rods, posterior…
-
China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study
•
Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the bivalent human papillomavirus (HPV) vaccine Cecolin, co-developed by Xiamen Innovax Biotech Co., Ltd and Xiamen University. The vaccine, approved in China since December 2019, demonstrated 100% protective efficacy against high-grade genital lesions associated with HPV…
-
Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its next-generation epidermal growth factor receptor (EGFR) inhibitor sunvozertinib (DZD9008) combined with bevacizumab in locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutation. Ongoing…
-
MofCOM’s 2021 Pharma Distribution Report Shows Market Recovery
•
The Ministry of Commerce (MofCOM) released its annual statistical review of the pharma distribution industry for 2021, highlighting steady growth and recovery to pre-pandemic levels. The report indicates that the national pharmaceutical distribution market has rebounded, with total sales of the seven major categories of pharmaceutical commodities (including devices and…
-
NHSA Issues Notice on Special Treatment of Oral Implant Medical Service Charges
•
The National Healthcare Security Administration (NHSA) has released a Notice on “Carrying out Special Treatment of Oral Implant Medical Service Charges and Consumables Prices.” The document, which refines the draft proposal issued last month, classifies oral implantation expenses based on treatment goals and provides detailed implementation timelines and measures. Cost…
-
Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer
•
The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody drug conjugate (ADC) co-developed by Keymed Biosciences Inc. and Lepu Biopharma Co., Ltd, has obtained breakthrough therapy designation (BTD) status. The designation is specifically for the drug’s potential use in CLDN18.2-positive advanced gastric cancer in…
-
Realcan Pharma and AWS Expand Partnership for Digital Transformation
•
China-based Realcan Pharmaceutical Group Co., Ltd (SHE: 002589) and Amazon Web Services (AWS) have agreed on a second phase partnership, with AWS becoming Realcan’s preferred cloud service provider to support its digital transformation. Financial details of the deal were not disclosed. Building on a Strong FoundationThe two companies first partnered…
-
Salipro Biotech Secures Patent Protection for Membrane Protein Stabilization Tech
•
Sweden-based Salipro Biotech AB announced that its core technology for stabilizing membrane proteins for drug development has been granted patent protection in China and the United States. The patent, titled “Saposin lipoprotein particles and libraries from crude membranes,” has been awarded by the China National Intellectual Property Administration (Chinese Patent…
-
Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction
•
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in a Phase I clinical study for its STP705, targeting adult abdominal fat reduction. The study, expected to report results during the first half of 2023, marks a significant step forward in the development of non-invasive…
